Startup Intros
FeaturesPricingNewsletterEventsPartners
FeaturesPricingNewsletterEventsPartners
  1. Home
  2. /Organizations
  3. /Andera Partners
Andera Partners logo

Andera Partners

ActiveVenture Capital
Website LinkedIn X
Updated: Jan 22, 2026 ·
AboutNewsFinancialsTeamDeep DiveFAQs

Quick Facts

Type
Investment Firm
Status
Active
Founded
1953
HQ
San Francisco, California
IPO Status
Private

Subscribe, Save or Share

Get email updates

Financial History

Total Raised
N/A
Valuation
N/A

Leadership Team

Key people at Andera Partners.

MP
Mathieu Pieronne
Investor
LF
Laurent Fichter
Partner
ER
Etienne Rossignol
Investor
LT
Laurent Tourtois
Partner
NA
Nicolas Aftimos
Investor
FD
Fadwa Dardar
Associate
GA
Guy Auger
Partner
SB
Stéphane Bergez
Partner
FG
Florian Gerard-Mercier
Analyst
VB
Vincent Bazzocchi
Investor
EC
Elyes Chouaieb
Investor
OL
Olivier Le Gall
Partner
AG
Antoine Guérillon
Associate
SC
Sylvain Charignon
Partner
SI
Sofia Ioannidou
Partner
AM
Arthur Milliard
Investor
LB
Léopold Brichard
Investor
OL
Olivier Litzka
Partner
PF
Pierre Flin
Analyst
FX
Francois Xavier Mauron
Partner
MC
Mayeul Caron
Partner
RW
Raphael Wisniewski
Associate
VC
Vincent Croci
Analyst
AF
Arnaud Faure
Partner
PW
Pierre-Luc Wilain de Leymarie
Associate
YY
Yuexin Yu
Investor
JJ
Julia Joannot
Associate
FG
Francesco Gonzaga
Investor
PP
Pierre-Yves Poirier
Partner
Startup Intros

Making merit matter more than network. The intelligence layer for Venture fundraising.

Platform

FeaturesPricingBlogNewsletterEvents

Company

PartnersAboutPrivacyTerms

Connect

© 2026 Startup Intros. All rights reserved.

Leadership Team

Key people at Andera Partners.

Mathieu Pieronne
Mathieu Pieronne
Investor
Laurent Fichter
Laurent Fichter
Partner
Etienne Rossignol
Etienne Rossignol
Investor
Laurent Tourtois
Laurent Tourtois
Partner
Nicolas Aftimos
Nicolas Aftimos
Investor
Fadwa Dardar
Fadwa Dardar
Associate
Guy Auger
Guy Auger
Partner
Stéphane Bergez
Stéphane Bergez
Partner
Florian Gerard-Mercier
Florian Gerard-Mercier
Analyst
Vincent Bazzocchi
Vincent Bazzocchi
Investor
Elyes Chouaieb
Elyes Chouaieb
Investor
Olivier Le Gall
Olivier Le Gall
Partner
Antoine Guérillon
Antoine Guérillon
Associate
Sylvain Charignon
Sylvain Charignon
Partner
Sofia Ioannidou
Sofia Ioannidou
Partner
Arthur Milliard
Arthur Milliard
Investor
Léopold Brichard
Léopold Brichard
Investor
Olivier Litzka
Olivier Litzka
Partner
Pierre Flin
Pierre Flin
Analyst
Francois Xavier Mauron
Francois Xavier Mauron
Partner
Mayeul Caron
Mayeul Caron
Partner
Raphael Wisniewski
Raphael Wisniewski
Associate
Vincent Croci
Vincent Croci
Analyst
Arnaud Faure
Arnaud Faure
Partner
Pierre-Luc Wilain de Leymarie
Pierre-Luc Wilain de Leymarie
Associate
Yuexin Yu
Yuexin Yu
Investor
Julia Joannot
Julia Joannot
Associate
Francesco Gonzaga
Francesco Gonzaga
Investor
Pierre-Yves Poirier
Pierre-Yves Poirier
Partner

Deep Dive

Andera Partners is a leading European private equity firm with over 20 years of experience, managing more than €5 billion in assets and supporting around 350 companies. Its mission centers on partnering with entrepreneurs and management teams to foster strong, sustainable growth through tailored investment strategies. The firm invests primarily in sectors such as life sciences, mobility and transportation, deep tech, Web3/blockchain, and ecological transition, leveraging its expertise to help companies innovate and adapt in rapidly changing markets[1][2][4][5].

Founded in the early 2000s, Andera Partners is structured as a partnership managed by a board of 10 partners and employs nearly 100 professionals. The firm has evolved to cover a broad range of private equity strategies, including mid-cap buyouts, growth capital, co-investments, and infrastructure investments, with a strong focus on responsible investing and sustainability—being carbon neutral since 2018. Its origin story highlights a commitment to collaboration and long-term value creation, emphasizing the "Power of And" philosophy, which reflects its belief in partnership and collective engagement[2][4].

Core Differentiators

  • Unique Investment Model: Andera Partners combines diverse private equity strategies (mid-cap, growth, life sciences, infrastructure) under one roof, allowing flexible and bespoke investment solutions.
  • Network Strength: With offices in Paris, Antwerp, and Munich, and a broad European and US reach, it leverages extensive industry and entrepreneurial networks.
  • Track Record: Over 20 years, it has supported 350 companies and managed billions in assets, demonstrating consistent growth and successful exits.
  • Operating Support: The firm offers a dedicated transformation program providing strategic advice, digital transformation, CSR, M&A, and international development support to portfolio companies[1][2][5].

Role in the Broader Tech Landscape

Andera Partners rides the wave of increasing demand for innovation-driven growth and sustainable business models in Europe and beyond. Its timing aligns with growing investor interest in sectors like life sciences, deep tech, and ecological transition, supported by favorable regulatory and market conditions. By actively supporting digital transformation and sustainability initiatives, Andera influences the broader ecosystem by enabling companies to scale responsibly and adapt to global challenges such as climate change and technological disruption[1][2][4].

Quick Take & Future Outlook

Looking ahead, Andera Partners aims to expand its assets under management to €7–8 billion by 2028, signaling ambitions for deeper market penetration and broader sector coverage. Trends shaping its journey include the acceleration of digital and green technologies, increased focus on ESG (environmental, social, governance) criteria, and cross-border investment opportunities. Its influence is likely to grow as it continues to blend financial expertise with operational support, fostering innovation and sustainability in its portfolio companies and the wider private equity landscape[1][2][4]. The firm's collaborative ethos and strategic adaptability position it well to capitalize on evolving market dynamics and emerging growth sectors.

Sources

  1. mtec-sc.org
  2. anderapartners.com
  3. privatecapital.be
  4. eu-startups.com
  5. anderapartners.com
  6. ivc-online.com
  7. preqin.com

Financial History

Total Raised
N/A
Valuation
N/A

Investments Made

DateCompanyRoundLead Investor(s)Co-Investor(s)
Nov 1, 2025Artios Pharma$120.0M Series D—EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Pfizer Venture Investments
Oct 1, 2025Adcytherix$120.0M Series A—Pontifax Venture Capital
Oct 1, 2025Tubulis$360.0M Series C—5AM Ventures, Abingworth, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures
Feb 1, 2025EG 427$28.0M Series B—EQT Life Sciences, Kurma Partners, Pontifax Venture Capital
Dec 1, 2024GEMMABio$34.0M Seed—Earlybird Venture Capital, Kurma Partners, Pfizer Venture Investments, Pureos Bioventures, Wellington Partners, Vincent Brichard
Nov 1, 2024ADCendo$140.0M Series B—Access Biotechnology, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital
Oct 1, 2024Evommune$120.0M Series C—Arix Bioscience, Pivotal bioVenture Partners, RA Capital, Ysios Capital
Sep 1, 2024Skysun$19.0M Series A——
Jul 1, 2024SciRhom$68.0M Series A—Deerfield Management
Jul 1, 2024Asceneuron$100.0M Series C—5AM Ventures, Abingworth, ARCH Venture Partners, EQT Life Sciences, Leaps by Bayer, MRL Ventures Fund, Hakan Goker, M Ventures (Merck), Soffinova Partners, Takeda Ventures, Versant Ventures
Jun 1, 2024Adcytherix$32.0M Seed—Canaan Partners, EQT Life Sciences, Pontifax Venture Capital
Jun 1, 2024Bright Peak Therapeutics$90.0M Series C—Versant Ventures, Josh Resnick
Apr 1, 2024Alterome Therapeutics$130.0M Series B—Nextech Invest, OrbiMed, venBio, Vida Ventures
Mar 1, 2024Capstan Therapeutics$180.0M Series B—Amorchem, Earlybird Venture Capital, Forbion, Kurma Partners, Ed Mathers, Pfizer Venture Investments, Pureos Bioventures, Wellington Partners, Vincent Brichard
Mar 1, 2024Tubulis$140.0M Series B—5AM Ventures, Abingworth, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures
Feb 1, 2024MMI$110.0M Series C—Atlas Venture, Bain Capital Life Sciences, Deerfield Management
Jan 1, 2024ENYO Pharma$28.0M Series C—Earlybird Venture Capital, Kurma Partners, OrbiMed, Pfizer Venture Investments, Pureos Bioventures, SR One, Third Rock Ventures, Wellington Partners, Vincent Brichard
Nov 1, 2023Nouscom$73.0M Series C—5AM Ventures, Abingworth, EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Versant Ventures
Oct 1, 2023AgomAb Therapeutics$100.0M Series C—Canaan Partners, EQT Life Sciences, Forbion, HealthCap, INKEF Capital, Kurma Partners, Pontifax Venture Capital, Soffinova Partners
Oct 1, 2023Minervax$57.0M Venture Round—Adjuvant Capital, Earlybird Venture Capital, Kurma Partners, Pfizer Venture Investments, Pureos Bioventures, Sanofi Ventures, T1D Fund, Wellington Partners, Vincent Brichard
Apr 1, 2023BioVentrix$49.0M Series A——
Apr 1, 2023ADCendo$34.0M Series A—Access Biotechnology, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital
Apr 1, 2023Ariceum Therapeutics$25.0M Series A—Earlybird Venture Capital, HealthCap, Pureos Bioventures, RA Capital, Ysios Capital
Apr 1, 2023Complement Therapeutics$79.0M Series A—Max Klement, Cambridge Innovation Capital, EQT Life Sciences, Forbion, Kurma Partners, Sanofi Ventures, Ysios Capital
Jan 1, 2023SoniVie$60.0M Series C—OrbiMed